Equity Research Diagnostics & Research

Should You Buy Agilent Technologies, Inc. Stock in 2026?

By CirclFi Research Team · · 13/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Agilent Technologies, Inc. (A) ranks in the top tier of our coverage universe with a Quality of Company score of 10.0/10. Trading at a market price of $131.45, this high-quality profile requires careful comparison against our 13 intrinsic value models.

The short answer: 0 of 13 CirclFi valuation models project upside for Agilent Technologies, Inc. (A) at $131.44 — the model consensus leans bearish, with a Quality Score of 10.0/10 and Value-Trap risk of 18/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 13 of 13 models suggest overvaluation — majority bearish
  • Quality Score: 10.0/10 — Excellent — top-tier fundamentals
  • Value Trap Risk: 18/100 — Minimal — healthy fundamentals
  • Fair Value Range: $5.26 – $130.36 (2379% spread)

Bullish Models

0 / 13

Bearish Models

13 / 13

Quality Score

10.0 /10

Excellent — top-tier fundamentals

Value Trap Risk

18 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

13 /13
Active Models

Avg. confidence: 55%

Investment Thesis

The Bull Case

Currently, no active models project meaningful upside for A at $131.44. Bulls might argue that qualitative factors not captured by quantitative models could unlock value not reflected in current estimates.

The Bear Case

Target: $5.26 (-96.0%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $5.26 (-96.0%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +95.2% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
  • Industry headwind: drug pricing legislation represents a meaningful risk for Agilent Technologies, Inc. and its Diagnostics & Research peers.

Peer Benchmarking

IDXX IDEXX Laboratories,
10.0
MEDP Medpace Holdings, In
10.0
MTD Mettler-Toledo Inter
9.2
CSTL Castle Biosciences,
9.2
DHR Danaher Corporation
9.1

Valuation Divergence

Spread

2379%

Fair Value Range

$5.26 – $130.36

A 2379% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

PWERM

$130.36 (-0.8%)

Most Bearish

Dynamic NAV

$5.26 (-96.0%)

Key Risk Factors

Model Disagreement

2379% spread signals high variance in projections.

Bearish Consensus

13/13 models suggest overvaluation.

Macro/Sector Risk

Diagnostics & Research headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View A Data Page →

The Bottom Line

Our valuation engine sends a clear cautionary signal on Agilent Technologies, Inc. at $131.45. 12/13 models flag overvaluation, composite fair value sits at $71.49 (-45.6%), and the risk-reward profile appears unfavorable. Quality at 10.0/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Agilent Technologies, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy A stock right now?

Based on CirclFi's multi-model analysis, 0 of 13 models see upside for A at $131.44. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Agilent Technologies, Inc.?

Key risks include: wide model disagreement (2379% spread), signaling high uncertainty; general market and sector-specific risks affecting Diagnostics & Research companies. Always diversify and consult a financial advisor.

How does A compare to its competitors?

Among Diagnostics & Research peers, A holds a Quality Score of 10.0/10. Comparable companies include IDXX (QOC 10.0), MEDP (QOC 10.0), MTD (QOC 9.2). The relative ranking helps investors identify whether A offers better fundamental quality than alternatives in the same sector.

Is A a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. A's Quality Score of 10.0/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy A at?

CirclFi does not provide target buy prices or price alerts. However, our 13 active models produce fair value estimates ranging from $5.26 to $130.36. At $131.44, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for A.

View A Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →